Molecular typing relies on molecular genetic screening and is not however routinely offered. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple detrimental) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 might be handy, https://marjaneyp529fnw6.mysticwiki.com/user